Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 6/20 | 1.00 |
| ▸ | TSHR | P16473 | 5/20 | 1.00 |
| ▸ | SLC9A1 | P19634 | 5/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | THPO | P40225 | 3/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 3/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 1.00 |
| ▸ | GMNN | O75496 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 1.00 |
| ▸ | SLC9A5 | Q14940 | 10/20 | 0.72 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.70 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.70 |
| ▸ | MAPT | P10636 | 1/20 | 0.68 |
| ▸ | RAD52 | P43351 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 5-(N-Methyl-N-Isobutyl)Amiloride SCHEMBL29404271 | 1.00 | CYP1A2 (1.00) | CYP1A2TSHRSLC9A1CYP2D6MEN1 | |
| SCHEMBL14513859 | 0.86 | SLC9A5 (0.77) | CYP1A2TSHRSLC9A1CYP2D6MEN1 | |
| SCHEMBL14504165 | 0.84 | SLC9A5 (0.73) | CYP1A2TSHRSLC9A1CYP2D6MEN1 | |
| SCHEMBL2432734 | 0.83 | CYP1A2 (0.70) | CYP1A2TSHRSLC9A1CYP2D6MEN1 | |
| SCHEMBL29406659 | 0.83 | CYP1A2 (1.00) | CYP1A2TSHRSLC9A1CYP2D6MEN1 | |
| SCHEMBL9852481 | 0.83 | CYP1A2 (1.00) | CYP1A2TSHRSLC9A1CYP2D6MEN1 | |
| SCHEMBL2431417 | 0.81 | CYP1A2 (0.67) | CYP1A2TSHRSLC9A1CYP2D6MEN1 | |
| 5-(N-Ethyl-N-Isopropyl)Amiloride SCHEMBL29404178 | 0.80 | SLC9A5 (1.00) | CYP1A2TSHRSLC9A1CYP2D6MEN1 | |
| 5-(N-Ethyl-N-Isopropyl)Amiloride SCHEMBL9852524 | 0.80 | SLC9A5 (1.00) | CYP1A2TSHRSLC9A1CYP2D6MEN1 | |
| SCHEMBL14504168 | 0.79 | CYP1A2 (0.77) | CYP1A2TSHRSLC9A1CYP2D6MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0451130-A2 | Use of amiloride and other pyrazine derivatives for preventing or treating ocular neovascularization | CELTRIX PHARMACEUTICALS, INC. (US) | 1991-10-09 | — | — | EP | claimed |
| US-11192863-B2 | Antiviral compounds and methods | BIOTRON LIMITED (AU) | 2021-12-07 | — | — | US | disclosed |
| US-20210223233-A1 | Mitochondrial Conductance Inhibitors and Methods of Use Thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-07-22 | — | — | US | disclosed |
| US-10472332-B2 | Antiviral compounds and methods | BIOTRON LIMITED (AU) | 2019-11-12 | — | — | US | disclosed |
| US-20170260147-A1 | ANTIVIRAL COMPOUNDS AND METHODS | BIOTRON LIMITED (AU) | 2017-09-14 | — | — | US | disclosed |
| US-20170260147-A1 | ANTIVIRAL COMPOUNDS AND METHODS | BIOTRON LIMITED (AU) | 2017-09-14 | — | — | US | disclosed |
| US-20150313909-A1 | ANTIVIRAL COMPOUNDS AND METHODS | BIOTRON LIMITED (AU) | 2015-11-05 | — | — | US | disclosed |
| US-20150313909-A1 | ANTIVIRAL COMPOUNDS AND METHODS | BIOTRON LIMITED (AU) | 2015-11-05 | — | — | US | disclosed |
| US-20130035328-A1 | ANTIVIRAL COMPOUNDS AND METHODS | GAGE PETER WILLIAM (AU) | 2013-02-07 | — | — | US | disclosed |
| US-20130035328-A1 | ANTIVIRAL COMPOUNDS AND METHODS | GAGE PETER WILLIAM (AU) | 2013-02-07 | — | — | US | disclosed |
| US-20070099968-A1 | Antiviral compounds and methods | BIOTRON LIMITED (AU) | 2007-05-03 | — | — | US | disclosed |
| US-20070099968-A1 | Antiviral compounds and methods | BIOTRON LIMITED (AU) | 2007-05-03 | — | — | US | disclosed |
| EP-0451130-A2 | Use of amiloride and other pyrazine derivatives for preventing or treating ocular neovascularization | CELTRIX PHARMACEUTICALS, INC. (US) | 1991-10-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11192863-B2 | Antiviral compounds and methods | MAVS, ZC3HAV1, EIF2AK2 | CYP1A2 3645/4885TSHR 4658/4885SLC9A1 4403/4885 |
| US-10472332-B2 | Antiviral compounds and methods | MAVS, ZC3HAV1, EIF2AK2 | CYP1A2 3645/4885TSHR 4658/4885SLC9A1 4403/4885 |
| US-20070099968-A1 | Antiviral compounds and methods | MAVS, ZC3HAV1, EIF2AK2 | CYP1A2 3324/4885TSHR 4665/4885SLC9A1 4386/4885 |
| US-20210223233-A1 | Mitochondrial Conductance Inhibitors and Methods of Use Thereof | NLN, MCU, SLC8B1 | CYP1A2 3370/4885TSHR 3770/4885SLC9A1 304/4885 |
| US-20170260147-A1 | ANTIVIRAL COMPOUNDS AND METHODS | MAVS, ZC3HAV1, EIF2AK2 | CYP1A2 3645/4885TSHR 4658/4885SLC9A1 4403/4885 |
| US-20130035328-A1 | ANTIVIRAL COMPOUNDS AND METHODS | ZC3HAV1, MAVS, EIF2AK2 | CYP1A2 3795/4885TSHR 4699/4885SLC9A1 4316/4885 |
| US-20150313909-A1 | ANTIVIRAL COMPOUNDS AND METHODS | ZC3HAV1, MAVS, EIF2AK2 | CYP1A2 3795/4885TSHR 4699/4885SLC9A1 4316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.